Shire Adds To HGT Unit With Lotus Acquisition; Gets Preclinical Rare Disease Treatment
This article was originally published in The Pink Sheet Daily
Executive Summary
Shire makes a bolt-on acquisition that will complement both its rare disease franchise and its regenerative medicines unit.